Arthur F. Ryan, an insider at Regeneron Pharmaceuticals, Inc. (REGN), reported a small sale of company common stock that occurred on July 2, 2026. The transaction involved the sale of 200 shares of Regeneron common stock. The shares were sold under a prearranged trading plan intended to comply with Rule 10b5-1(c), which Ryan adopted on October 31, 2025. Such plans allow insiders to schedule future trades in advance, helping reduce concerns that transactions are based on material nonpublic information. The filing states that the 200 shares were sold at a volume-weighted average price, with individual sale prices ranging from $650.10 to $650.19 per share. Based on that range, the sale generated approximately $130,000 in gross proceeds before commissions, taxes or other costs. The filing notes that Ryan will provide detailed price-by-price information for the July 2 sales upon request by SEC staff, Regeneron or a company security holder. The document excerpt does not show the full Form 4 transaction table, including the specific transaction code or Ryan’s beneficial ownership after the sale. However, the narrative footnotes make clear that the reported action was a disposition of Regeneron common stock through a Rule 10b5-1 trading plan. Ryan signed the filing on July 7, 2026.